Sleep disturbances in craniopharyngioma: a systematic review and meta-analysis
Abstract
Background: Craniopharyngioma is a rare, parasellar tumor of low histological malignancy (WHO grade 1) arising from remnants of the Rathke pouch, which can disrupt hypothalamic modulation. Sleep disturbances, including excessive daytime sleepiness (EDS), are commonly reported in patients with craniopharyngioma, although findings have been inconsistent. This systematic review and meta-analysis was conducted to aggregate prior sleep-related findings in craniopharyngioma patients, with the aim of determining the prevalence and severity of sleep disorders, as well as quantifying alterations in sleep structure and sleep breathing.
Method: Databases including PubMed, Web of Science, EBSCO, and Cochrane library were searched up through April 8, 2025, to identify studies investigating sleep disturbances in craniopharyngioma patients. Random-effect meta-analysis was employed to calculate the pooled proportion of patients with sleep disorders, pooled means of sleep scale and polysomnography parameters, and the standard mean difference in sleep parameters between craniopharyngioma patients and control group.
Results: A total of 22 studies, encompassing 1137 patients and 370 matched controls, were included. The meta-analysis revealed that the pooled mean score of Pittsburgh sleep quality index in craniopharyngioma patients was 6.76 (95% CI: 6.17-7.35). The overall prevalence of EDS was 50% (95% CI: 40%-61%), with a higher estimate from the multiple sleep latency test (MSLT) (55%, 95%…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,137 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.